Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

BioEscalator building with BioEscalator logo and University of Oxford logo

A new venture for the University of Oxford Medical Sciences Division, the BioEscalator was established to provide much-needed high-quality commercial laboratory space for the growing number of healthcare-focused spin-out companies being created by academics and researchers across the University. With its mission of teaching and research at the fore, the University was also keen for the space to be available to all small early-stage biotech start-ups working with University academics and clinicians. The requirement was not just space and shared facilities, but also support and community. Its unique location - between the University’s medical research buildings and Oxford’s main hospitals - facilitates access to the rich mix of expertise, knowledge, and resources available across Oxford and beyond.

The results have been extremely positive. Since the BioEscalator opened its doors in 2018, 24 companies have started their journeys there. Ten of these have been Oxford University spin-outs representing nine different academic departments. The steadily growing community has matured to a diverse mix of biotech SMEs, working on novel diagnostics, therapeutics and platform technologies applicable to a wide range of diseases, including cancer, autoimmune disorders, infectious diseases and metabolic disorders. Three of the companies even pivoted their research to support the fight against covid-19. Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans to develop new detection methods and discover potential therapeutics. Alchemab was also a member of the BIA Antibody Taskforce.

Despite their infancy, and the challenges of a global pandemic, the BioEscalator companies have been hugely successful at raising funds to support high growth. Over the three years, they have collectively attracted £1.4B, of which £1.2B was raised in the past 12 months. Seven companies have graduated from the BioEscalator, thanks to successful fundraising, and moved on to the next stage in their journey, including two tenants (oncolytic virus developer Theolytics and herbicide innovator MoA Technology), who was among the first to join the BioEscalator community. They are now part of the esteemed alumni community, along with fellow BioEscalator graduates, OMass Therapeutics, MiroBio, EnaraBio and Alchemab. The smaller SMEs continue to grow within the BioEscalator, in many cases moving from a bench or two in the shared Innovation Labs to a proprietary lab and office space as they meet their milestones and recruit new talent. Overall, the BioEscalator has generated over 180 jobs so far.

Read the full story on the BioEscalator website

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.